Effects of glucocorticoid treatment on bone strength

Andrew S. Manolides, Diane M. Cullen, Mohammed P. Akhter

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Glucocorticoids (GCs) are prescribed for the treatment of several diseases, but their long-term use causes osteoporosis. Current research suggests that GCs suppress the canonical Wnt/β pathway, resulting in decreased expression of critical bone proteins. This study examined how bone structure and strength of high bone mass (HBM) mice and low density lipoprotein receptor-related protein 5 (LRP5) knockout (KO+/-) mice are affected by GC treatment in comparison to wild-type (WT) mice, and if changes were specific to either trabecular or cortical bone. Mice were treated with either prednisone or placebo. The femurs and L4 vertebral bodies were analyzed by micro-CT for structure and mechanically tested to determine strength and apparent material strength properties. Differences in all measured variables corresponding to GC treatment and genotype were tested using two-way ANOVA. GC treatment caused decreased structural strength parameters, weakened apparent material strength properties, and disruption of bone structure in HBM, but not LRP5+/- or WT, mice. Despite treatment-related loss, trabecular bone structure and strength remained elevated as compared to LRP5+/- and WT mice. In HBM femurs, both cortical and trabecular structure, but not strength parameters, were negatively affected by treatment. In HBM vertebral bodies, both structural and strength parameters were negatively affected by treatment.

Original languageEnglish
Pages (from-to)532-539
Number of pages8
JournalJournal of Bone and Mineral Metabolism
Volume28
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Glucocorticoids
Bone and Bones
Low Density Lipoprotein Receptor-Related Protein-5
Femur
Therapeutics
Wnt Signaling Pathway
Prednisone
Knockout Mice
Osteoporosis
Analysis of Variance
Genotype
Placebos
Research
Proteins

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Effects of glucocorticoid treatment on bone strength. / Manolides, Andrew S.; Cullen, Diane M.; Akhter, Mohammed P.

In: Journal of Bone and Mineral Metabolism, Vol. 28, No. 5, 09.2010, p. 532-539.

Research output: Contribution to journalArticle

Manolides, Andrew S. ; Cullen, Diane M. ; Akhter, Mohammed P. / Effects of glucocorticoid treatment on bone strength. In: Journal of Bone and Mineral Metabolism. 2010 ; Vol. 28, No. 5. pp. 532-539.
@article{4a322bf81a3743498044190c364a46cb,
title = "Effects of glucocorticoid treatment on bone strength",
abstract = "Glucocorticoids (GCs) are prescribed for the treatment of several diseases, but their long-term use causes osteoporosis. Current research suggests that GCs suppress the canonical Wnt/β pathway, resulting in decreased expression of critical bone proteins. This study examined how bone structure and strength of high bone mass (HBM) mice and low density lipoprotein receptor-related protein 5 (LRP5) knockout (KO+/-) mice are affected by GC treatment in comparison to wild-type (WT) mice, and if changes were specific to either trabecular or cortical bone. Mice were treated with either prednisone or placebo. The femurs and L4 vertebral bodies were analyzed by micro-CT for structure and mechanically tested to determine strength and apparent material strength properties. Differences in all measured variables corresponding to GC treatment and genotype were tested using two-way ANOVA. GC treatment caused decreased structural strength parameters, weakened apparent material strength properties, and disruption of bone structure in HBM, but not LRP5+/- or WT, mice. Despite treatment-related loss, trabecular bone structure and strength remained elevated as compared to LRP5+/- and WT mice. In HBM femurs, both cortical and trabecular structure, but not strength parameters, were negatively affected by treatment. In HBM vertebral bodies, both structural and strength parameters were negatively affected by treatment.",
author = "Manolides, {Andrew S.} and Cullen, {Diane M.} and Akhter, {Mohammed P.}",
year = "2010",
month = "9",
doi = "10.1007/s00774-009-0156-5",
language = "English",
volume = "28",
pages = "532--539",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Effects of glucocorticoid treatment on bone strength

AU - Manolides, Andrew S.

AU - Cullen, Diane M.

AU - Akhter, Mohammed P.

PY - 2010/9

Y1 - 2010/9

N2 - Glucocorticoids (GCs) are prescribed for the treatment of several diseases, but their long-term use causes osteoporosis. Current research suggests that GCs suppress the canonical Wnt/β pathway, resulting in decreased expression of critical bone proteins. This study examined how bone structure and strength of high bone mass (HBM) mice and low density lipoprotein receptor-related protein 5 (LRP5) knockout (KO+/-) mice are affected by GC treatment in comparison to wild-type (WT) mice, and if changes were specific to either trabecular or cortical bone. Mice were treated with either prednisone or placebo. The femurs and L4 vertebral bodies were analyzed by micro-CT for structure and mechanically tested to determine strength and apparent material strength properties. Differences in all measured variables corresponding to GC treatment and genotype were tested using two-way ANOVA. GC treatment caused decreased structural strength parameters, weakened apparent material strength properties, and disruption of bone structure in HBM, but not LRP5+/- or WT, mice. Despite treatment-related loss, trabecular bone structure and strength remained elevated as compared to LRP5+/- and WT mice. In HBM femurs, both cortical and trabecular structure, but not strength parameters, were negatively affected by treatment. In HBM vertebral bodies, both structural and strength parameters were negatively affected by treatment.

AB - Glucocorticoids (GCs) are prescribed for the treatment of several diseases, but their long-term use causes osteoporosis. Current research suggests that GCs suppress the canonical Wnt/β pathway, resulting in decreased expression of critical bone proteins. This study examined how bone structure and strength of high bone mass (HBM) mice and low density lipoprotein receptor-related protein 5 (LRP5) knockout (KO+/-) mice are affected by GC treatment in comparison to wild-type (WT) mice, and if changes were specific to either trabecular or cortical bone. Mice were treated with either prednisone or placebo. The femurs and L4 vertebral bodies were analyzed by micro-CT for structure and mechanically tested to determine strength and apparent material strength properties. Differences in all measured variables corresponding to GC treatment and genotype were tested using two-way ANOVA. GC treatment caused decreased structural strength parameters, weakened apparent material strength properties, and disruption of bone structure in HBM, but not LRP5+/- or WT, mice. Despite treatment-related loss, trabecular bone structure and strength remained elevated as compared to LRP5+/- and WT mice. In HBM femurs, both cortical and trabecular structure, but not strength parameters, were negatively affected by treatment. In HBM vertebral bodies, both structural and strength parameters were negatively affected by treatment.

UR - http://www.scopus.com/inward/record.url?scp=77956924319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956924319&partnerID=8YFLogxK

U2 - 10.1007/s00774-009-0156-5

DO - 10.1007/s00774-009-0156-5

M3 - Article

VL - 28

SP - 532

EP - 539

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 5

ER -